<!DOCTYPE html>
<html>
<head>
	<title>Targeted Therapies by Pathway</title>
	<link rel="stylesheet" type="text/css" href="../css/normalize.css">
	<link rel="stylesheet" type="text/css" href="../css/index.css">
</head>
<body>
	
	<header>
		<h1>Targeted Therapy by Pathway</h1>
		<form>
			<input type="text" name="search" placeholder="Search">
		</form>
	</header>
	
	<nav>
		<ul id="pathwayList">
			<li id="mapk" class="pathway">MAPK</li>
			<li id="egfr" class="pathway">EGFR/HER2</li>
			<li id="vegf" class="pathway">VEGF/VEGFR</li>
			<li id="mtor" class="pathway">PI3K/AKT</li>
		</ul>
	</nav>
	<main >
		<section>
			<h2>MAPK Pathway</h2>
			<div class="background-image">
				<p id="BRAF" class="proteinTarget">BRAF</p>
				<p id="MEF" class="proteinTarget">MEF</p>
			</div>

			<p>The MAPK pathway consists of a cascade of serine/threonine kinases that are activated downstream of the active Ras GTPase. Conical members of the pathway are MAPKKK (RAF), MAPKK (MEK), and MAPK (Erk1/2). Targeted therapies against the MAPK pathway in clinical use include BRAF and MEK inhibitors</p>
		</section>
		<figcaption>
			<!--page starts with no displayswitch class. Added with javascript-->
			<p id="braf-p" >BRAF is mutated in 90% of melanomas. Several BRAF inhibitors have been approved by the FDA.</p>
			<p id="mef-p" class="displayswitch">MEF operates downstream of mutant BRAF. FDA approved drugs targeting MEF are used as a means of circumventing resistance to BRAF inhibitors.</p>

		</figcaption>
	</main>
	<footer>
		<!--Content still being decided-->
	</footer>

<!-- JAVASCRIPT -->
<script></script>
<script></script>
</body>
</html>